Skip to content

Innovative

Targeted Therapeutics

Using Energy Based Systems

Focal Medical is a biopharmaceutical company developing novel, targeted therapeutic products.  We apply our sophisticated technology platforms to revolutionize the way drugs are empowered to precisely target diseased cells and dramatically improve healthcare outcomes. 

Our goal is to maximize the potency of drug therapy whilst reducing side effects and thereby yield better outcomes for patients

Group 40

Innovation in

Drug Delivery

Using Energy Based Systems

At Focal Medical, we’re applying our sophisticated technology platforms to revolutionize the way drugs are delivered to improve patient healthcare outcomes. Our goal is to reduce side effects, maximize the potency of drug therapy and yield better outcomes for patients.

Group 40

  intro

Delivering Targeted Therapeutics

Precision drug targeting is important:

  • In cases where a single organ is the target of treatment, systemic drug delivery may result in only limited exposure of the target organ to the therapeutic agent.
  • Drugs, when delivered systemically, may have negative effects on the whole body, these effects may limit the tolerable drug dose.

To address these shortcomings, Focal Medical’s products use a precisely targeted energy field for the precision delivery of drugs to their intended target.

Utilizing our approach, we believe drug therapy can deliver dramatically better health outcomes, enabling the treatment of otherwise intractable diseases. 

Lead program

New hope for pancreatic
cancer therapy

Our lead program pursues one of cancer’s most significant challenges —locally advanced nonresectable pancreatic adenocarcinoma.

  technology

New hope for pancreatic
cancer therapy

Our first program pursues one of cancer’s most significant unmet medical need — locally advanced pancreatic adenocarcinoma that’s unremovable at diagnosis. We expect to initiate our first clinical trial in 2023. Our confidence in this program is based on strong preclinical results from studies conducted at University of North Carolina – Chapel Hill and the significant unmet medical need which pancreatic patients face.

Benefits

Advantages of our approach

Our technology establishes an electric field at the delivery site, and actively delivers drug molecules precisely and specifically into target cells utilizing non-circulatory pathways.

Utilizes non-blood pathways to actively drive drug through barriers and resistance mechanisms directly to target cells.

Actively moves drug across the cellular wall, enhancing concentration and viability at its target site.

Reduces exposure of non-diseased tissue and associated unwanted side effects.

  meet the team

Experienced leadership in product development

Our veteran team bridges biotechnology and medical device manufacturing, with experience in both startups and established companies. Our technology emerged from the laboratories of a distinguished surgical oncologist and a renowned chemical engineer and entrepreneur at the University of North Carolina. 

In addition to our Series A, led by Khosla Ventures, we have secured multiple grants from the National Institutes of Health.

  meet the team

Experienced leadership in product development

Our veteran team bridges the gap between biotechnology and medical device manufacturing, with experience in both startups and established companies. Our technology emerged from the labs of a distinguished surgical oncologist and a renowned chemical engineer and entrepreneur at the University of North Carolina. In addition to Series A funding, we have secured several grants from the National Institutes of Health.

  news & updates

  news & updates

What we’ve been up to
Stay up to date
Follow us

Focal Medical, Inc.
111 James Jackson Ave. Suite 131
Cary, NC 27513

Focal Medical Copyright 2022 | Focal Medical is an equal opportunity employer
Terms of servicePrivacy policyOther policies 

Back To Top